Accuray Inc (ARAY)

[surf1944]

8:41AM Accuray: Presentations at radiation oncology meeting highlight CyberKnife prostate outcomes from patients at more than 40 centers (ARAY) 6.91 : Co announced today clinical findings using non-invasive CyberKnife? stereotactic body radiation therapy for the treatment of prostate cancer. Two studies presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston were selected by ASTRO for presentation to the media at a prostate-focused press conference on Tuesday, October 30, 2012, for which the use of CyberKnife SBRT for prostate cancer represented half of the press conference's focus. Patients were followed for a median of 36 months, and close to half were followed for at least four years, as updated by Dr. Katz during his presentation. Actuarial five-year disease-free survival was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients. These findings compare favorably with other surgical and radiation-based treatments